Please provide your email address to receive an email when new articles are posted on . An AI tool outperformed current FDA-approved biomarkers for predicting survival after immune checkpoint ...

General practitioner examining a patient's hand for signs of rheumatoid arthritis. A breakthrough in cancer and autoimmune disease therapy could unlock a whole new frontier in medicine. Scientists are ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

One of the best ways to defeat cancer is by rousing the immune system to attack it. Experts have thought that immune cells had to be inside of tumors for one type of immunotherapy, known as checkpoint ...

Subcutaneous immunotherapy injections for cancer, such as immune checkpoint inhibitors, are an emerging therapy that may replace some traditional intravenous infusions. Common side effects include ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S. The ...

Please provide your email address to receive an email when new articles are posted on . Black and Hispanic patients continue to be underrepresented in immune checkpoint inhibitor trials. Almost ...

Scientists have identified a hidden barrier that prevents immunotherapy from working against a rare liver cancer. Immunotherapy, which activates the body’s own immune system to kill cancer cells, has ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

It often starts with something small—a dark spot on the skin that looks a little off. A dermatologist takes a closer look, runs a biopsy, and soon after, the diagnosis arrives: melanoma. If the cancer ...

Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...